These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 39294672)

  • 1. Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study.
    Currado D; Saracino F; Ruscitti P; Marino A; Pantano I; Vomero M; Berardicurti O; Pavlych V; Di Vico C; Caso F; Costa L; Tasso M; Camarda F; Misceo F; De Vincenzo F; Corrado A; Arcarese L; Rigon A; Vadacca M; Corberi E; Kun L; Trunfio F; Pilato A; Lamberti L; Cantatore FP; Perosa F; Guggino G; Scarpa R; Cipriani P; Ciccia F; Giacomelli R; Navarini L
    Arthritis Res Ther; 2024 Sep; 26(1):162. PubMed ID: 39294672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pain catastrophizing in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: biopsychosocial perspective and impact on health-related quality of life.
    Wilk M; Łosińska K; Pripp AH; Korkosz M; Haugeberg G
    Rheumatol Int; 2022 Apr; 42(4):669-682. PubMed ID: 35098329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring pain catastrophizing and its associations with low disease activity in rheumatic inflammatory disorders.
    Wilk M; Pripp AH; Korkosz M; Haugeberg G
    Rheumatol Int; 2023 Apr; 43(4):687-694. PubMed ID: 36624289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depression/anxiety symptoms in axial spondyloarthritis and psoriatic arthritis patients in Serbia: a pilot study.
    Milutinovic S; Veljkovic K; Zlatanovic M; Radunovic G; Damjanov N
    Rheumatol Int; 2019 Sep; 39(9):1595-1605. PubMed ID: 31309294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
    Michelsen B; Ørnbjerg LM; Kvien TK; Pavelka K; Nissen MJ; Nordström D; Santos MJ; Koca SS; Askling J; Rotar Z; Gudbjornsson B; Codreanu C; Loft AG; Kristianslund EK; Mann HF; Ciurea A; Eklund KK; Vieira-Sousa E; Yazici A; Jacobsson L; Tomšič M; Löve TJ; Ionescu R; van der Horst-Bruinsma IE; Iannone F; Pombo-Suarez M; Jones GT; Hyldstrup LH; Krogh NS; Hetland ML; Østergaard M
    Rheumatology (Oxford); 2020 Sep; 59(9):2455-2461. PubMed ID: 31960053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry.
    Pombo-Suarez M; Sanchez-Piedra C; Garcia-Magallón B; Pérez-Gómez A; Manrique-Arija S; Martín-Doménech R; Colazo M; Campos C; Campos J; Del Pino-Montes J; Arteaga MJ; Cea-Calvo L; Díaz-González F; Gómez-Reino JJ
    Clin Rheumatol; 2021 Oct; 40(10):3979-3988. PubMed ID: 33907904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
    Benavent D; Muñoz-Fernández S; De la Morena I; Fernández-Nebro A; Marín-Corral J; Castillo Rosa E; Taberna M; Sanabra C; Sastre C;
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231220818. PubMed ID: 38146537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
    Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
    Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
    Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Iannone F; Santo L; Anelli MG; Bucci R; Semeraro A; Quarta L; D'Onofrio F; Marsico A; Carlino G; Casilli O; Cacciapaglia F; Zuccaro C; Falappone PC; Cantatore FP; Muratore M; Lapadula G
    Semin Arthritis Rheum; 2017 Aug; 47(1):108-114. PubMed ID: 28216195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
    Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
    Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
    Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
    Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
    Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
    Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
    Govoni M; Batalov A; Boumpas DT; D'Angelo S; De Keyser F; Flipo RM; Kellner H; Leroi H; Khalifa A
    Clin Exp Rheumatol; 2024 Mar; 42(3):642-650. PubMed ID: 37976120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High pain catastrophizing scores in one-fourth of patients on biotherapy for spondylarthritis or rheumatoid arthritis.
    Penhoat M; Saraux A; Le Goff B; Augereau P; Maugars Y; Berthelot JM
    Joint Bone Spine; 2014 May; 81(3):235-9. PubMed ID: 24321439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
    Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
    Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
    Christiansen SN; Ørnbjerg LM; Rasmussen SH; Loft AG; Askling J; Iannone F; Zavada J; Michelsen B; Nissen M; Onen F; Santos MJ; Pombo-Suarez M; Relas H; Macfarlane GJ; Tomsic M; Codreanu C; Gudbjornsson B; Van der Horst-Bruinsma I; Di Giuseppe D; Glintborg B; Gremese E; Pavelka K; Kristianslund EK; Ciurea A; Akkoc N; Barcelos A; Sánchez-Piedra C; Peltomaa R; Jones GT; Rotar Z; Ionescu R; Grondal G; Van de Sande MGH; Laas K; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2022 Aug; 61(9):3799-3807. PubMed ID: 34940840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.
    Michielsens CAJ; Boers N; den Broeder N; Wenink MH; van der Maas A; Mahler EAM; Mulder MLM; van der Heijde D; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Trials; 2020 Jan; 21(1):90. PubMed ID: 31941544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.